Selective killing of p53-deficient cancer cells by SP600125

EMBO Molecular Medicine

Volumn 4, Issue 6, 2012, Pages 500-514

  Jemaà, Mohamed ^a,b,c   Vitale, Ilio ^a,b,c   Kepp, Oliver ^a,b,c   Berardinelli, Francesco ^d   Galluzzi, Lorenzo ^a,b,c   Senovilla, Laura ^a,b,c   Mariño, Guillermo ^a,b,c   Malik, Shoaib Ahmad ^a,b,c   Rello Varona, Santiago ^a,b,c   Lissa, Delphine ^a,b,c   Antoccia, Antonio ^d   Tailler, Maximilien ^a,b,c   Schlemmer, Frederic ^a,b,c   Harper, Francis ^e   Pierron, Gérard ^e   Castedo, Maria ^a,b,c   Kroemer, Guido ^a,b,f,g,h  

^a Institut Gustave Roussy   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d ROMA TRE UNIVERSITY   (Italy)

^e CNRS   (France)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Caspases; HCT 116; High throughput screening; Mitochondrial outer membrane permeabilization; MPS1

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; MITOTIC KINASE MPS1; PHOSPHOTRANSFERASE; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL KILLING; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROSCOPY; MITOSIS; MOUSE; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT RESPONSE; TUMOR XENOGRAFT; VIDEOMICROSCOPY;

ANIMALS; ANTHRACENES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICROSCOPY, VIDEO; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861865998     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201200228     Document Type: Article

References (60)

1. Athar M, Elmets CA, Kopelovich L (2011) Pharmacological activation of p53 in cancer cells. Curr Pharm Des 17: 631- 639
2. Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M (2006) A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 20: 2687- 2700
3. Beckerman R, Prives C (2010) Transcriptional regulation by p53. Cold Spring Harb Perspect Biol 2: a000935
4. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, et al (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98: 13681- 13686
5. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862- 873
6. Castedo M, Ferri K, Roumier T, Metivier D, Zamzami N, Kroemer G (2002) Quantitation of mitochondrial alterations associated with apoptosis. J Immunol Methods 265: 39- 47
7. Castedo M, Coquelle A, Vivet S, Vitale I, Kauffmann A, Dessen P, Pequignot MO, Casares N, Valent A, Mouhamad S, et al (2006) Apoptosis regulation in tetraploid cancer cells. EMBO J 25: 2584- 2595
8. Cheok CF, Verma CS, Baselga J, Lane DP (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25- 37
9. Chu ML, Chavas LM, Douglas KT, Eyers PA, Tabernero L (2008) Crystal structure of the catalytic domain of the mitotic checkpoint kinase Mps1 in complex with SP600125. J Biol Chem 283: 21495- 21500
10. Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Perrera C, Depaolini SR, Rusconi L, Cucchi U, et al (2010) Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res 70: 10255- 10264
11. Davoli T, de Lange T (2011) The causes and consequences of polyploidy in normal development and cancer. Annual Rev Cell Dev Biol 27: 585- 610
12. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, et al (2007) A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 67: 6253- 6262
13. Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, Zhang X, Bleam M, Halsey W, Hughes A, et al (2010) Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther 9: 2079- 2089
14. Finkin S, Aylon Y, Anzi S, Oren M, Shaulian E (2008) Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy. Oncogene 27: 4411- 4421
15. Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, Kroemer G (2007) Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 12: 803- 813
16. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, et al (2009) Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 16: 1093- 1107
17. Galluzzi L, Morselli E, Kepp O, Vitale I, Pinti M, Kroemer G (2011a) Mitochondrial liaisons of p53. Antioxid Redox Signal 15: 1691- 1714
18. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2011b) Molecular mechanisms of cisplatin resistance. Oncogene, DOI: 10.1038/onc.2011.384
19. Ganem NJ, Storchova Z, Pellman D (2007) Tetraploidy, aneuploidy and cancer. Current Opin Genet Dev 17: 157- 162
20. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI (2006) The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 66: 7668- 7677
21. Green DR, Kroemer G (2009) Cytoplasmic functions of the tumour suppressor p53. Nature 458: 1127- 1130
22. Gu J, Zhang L, Swisher SG, Liu J, Roth JA, Fang B (2004) Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis. Oncogene 23: 1300- 1307
23. Ha GH, Baek KH, Kim HS, Jeong SJ, Kim CM, McKeon F, Lee CW (2007) p53 activation in response to mitotic spindle damage requires signaling via BubR1-mediated phosphorylation. Cancer Res 67: 7155- 7164
24. Heo YS, Kim SK, Seo CI, Kim YK, Sung BJ, Lee HS, Lee JI, Park SY, Kim JH, Hwang KY, et al (2004) Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J 23: 2185- 2195
25. Hewitt L, Tighe A, Santaguida S, White AM, Jones CD, Musacchio A, Green S, Taylor SS (2010) Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex. J Cell Biol 190: 25- 34
26. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, et al (2008) Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 68: 5301- 5308
27. Kepp O, Gottschalk K, Churin Y, Rajalingam K, Brinkmann V, Machuy N, Kroemer G, Rudel T (2009) Bim and Bmf synergize to induce apoptosis in Neisseria gonorrhoeae infection. PLoS Pathog 5: e1000348
28. Kim JA, Lee J, Margolis RL, Fotedar R (2010) SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition. Oncogene 29: 1702- 1716
29. Knight ZA, Lin H, Shokat KM (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10: 130- 137
30. Kuntzen C, Sonuc N, De Toni EN, Opelz C, Mucha SR, Gerbes AL, Eichhorst ST (2005) Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res 65: 6780- 6788
31. Kwiatkowski N, Jelluma N, Filippakopoulos P, Soundararajan M, Manak MS, Kwon M, Choi HG, Sim T, Deveraux QL, Rottmann S, et al (2010) Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol 6: 359- 368
32. Levesque AA, Kohn EA, Bresnick E, Eastman A (2005) Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. Oncogene 24: 3786- 3796
33. MacCorkle RA, Tan TH (2004) Inhibition of JNK2 disrupts anaphase and produces aneuploidy in mammalian cells. J Biol Chem 279: 40112- 40121
34. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G, Harel-Bellan A (2002) Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 99: 14849- 14854
35. Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Van Den Berg CL (2004) Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 23: 596- 604
36. Miyamoto-Yamasaki Y, Yamasaki M, Tachibana H, Yamada K (2007) Induction of endoreduplication by a JNK inhibitor SP600125 in human lung carcinoma A 549 cells. Cell Biol Int 31: 1501- 1506
37. Olaussen KA, Commo F, Tailler M, Lacroix L, Vitale I, Raza SQ, Richon C, Dessen P, Lazar V, Soria JC, et al (2009) Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene 28: 4249- 4260
38. Potapova O, Gorospe M, Dougherty RH, Dean NM, Gaarde WA, Holbrook NJ (2000) Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol 20: 1713- 1722
39. Rello-Varona S, Kepp O, Vitale I, Michaud M, Senovilla L, Jemaa M, Joza N, Galluzzi L, Castedo M, Kroemer G (2010) An automated fluorescence videomicroscopy assay for the detection of mitotic catastrophe. Cell Death Dis 1: e25
40. Santaguida S, Tighe A, D'Alise AM, Taylor SS, Musacchio A (2010) Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J Cell Biol 190: 73- 87
41. Schmidt M, Budirahardja Y, Klompmaker R, Medema RH (2005) Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep 6: 866- 872
42. Selivanova G (2010) Therapeutic targeting of p53 by small molecules. Semin Cancer Biol 20: 46- 56
43. Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223- 241
44. Shen H, Moran DM, Maki CG (2008) Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res 68: 8260- 8268
45. Sliedrecht T, Zhang C, Shokat KM, Kops GJ (2010) Chemical genetic inhibition of Mps1 in stable human cell lines reveals novel aspects of Mps1 function in mitosis. PLoS ONE 5: e10251
46. Stucke VM, Baumann C, Nigg EA (2004) Kinetochore localization and microtubule interaction of the human spindle checkpoint kinase Mps1. Chromosoma 113: 1- 115
47. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Jr., Kinzler KW, Vogelstein B, Papadopoulos N (2009) A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106: 3964- 3969
48. Talos F, Moll UM (2010) Role of the p53 family in stabilizing the genome and preventing polyploidization. Adv Exp Med Biol 676: 73- 91
49. Thompson SL, Compton DA (2010) Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol 188: 369- 381
50. Tritarelli A, Oricchio E, Ciciarello M, Mangiacasale R, Palena A, Lavia P, Soddu S, Cundari E (2004) p53 localization at centrosomes during mitosis and postmitotic checkpoint are ATM-dependent and require serine 15 phosphorylation. Mol Biol Cell 15: 3751- 3757
51. Vicencio JM, Ortiz C, Criollo A, Jones AW, Kepp O, Galluzzi L, Joza N, Vitale I, Morselli E, Tailler M, et al (2009) The inositol 1, 4, 5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death Differ 16: 1006- 1017
52. Vitale I, Galluzzi L, Vivet S, Nanty L, Dessen P, Senovilla L, Olaussen KA, Lazar V, Prudhomme M, Golsteyn RM, et al (2007) Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. PLoS ONE 2: e1337
53. Vitale I, Senovilla L, Galluzzi L, Criollo A, Vivet S, Castedo M, Kroemer G (2008) Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. Cell Cycle 7: 1956- 1961
54. Vitale I, Senovilla L, Jemaa M, Michaud M, Galluzzi L, Kepp O, Nanty L, Criollo A, Rello-Varona S, Manic G, et al (2010) Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. EMBO J 29: 1272- 1284
55. Vitale I, Galluzzi L, Castedo M, Kroemer G (2011) Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 12: 385- 392
56. Vousden KH, Prives C (2009) Blinded by the light: The growing complexity of p53. Cell 137: 413- 431
57. Vousden KH, Ryan KM (2009) p53 and metabolism. Nat Rev Cancer 9: 691- 700
58. Wang M, Atayar C, Rosati S, Bosga-Bouwer A, Kluin P, Visser L (2009) JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125. J Pathol 218: 95- 103
59. Wiman KG (2010) Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 29: 4245- 4252
60. Xu Q, Zhu S, Wang W, Zhang X, Old W, Ahn N, Liu X (2009) Regulation of kinetochore recruitment of two essential mitotic spindle checkpoint proteins by Mps1 phosphorylation. Mol Biol Cell 20: 10- 20